Byetta InfoSite

BYETTA offers sustained A1C control with a

secondary benefit of weight loss

Take control over A1C and sustain it through 2.5 years

With BYETTA, there is no increased risk of

hypoglycemia when used with metformin

and/or a thiazolidinedione (TZD)

Safety and tolerability: Details about hypoglycemia and nausea

Offer comparable efficacy to insulin

Similar A1C reductions as insulin glargine with significantly less hypoglycemia when used with metformin

BYETTA is easy to use and easy to add to

current therapies

Convenient, easy-to-use pen is simple to start

Indication:

BYETTA is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione, but have not achieved adequate glycemic control.

Important Safety Information for BYETTA^® (exenatide) injection

Precautions:

BYETTA is not a substitute for insulin in insulin-requiring patients. BYETTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Patients should be observed for signs and symptoms of acute pancreatitis (persistent severe abdominal pain which may be accompanied by vomiting). If pancreatitis is suspected, BYETTA and other potentially suspect drugs should be discontinued. Resuming treatment with BYETTA is not recommended if pancreatitis is confirmed and an alternative etiology for the pancreatitis has not been identified.
Patients should be observed for signs and symptoms of hypersensitivity reactions.
BYETTA is not recommended for use in patients with end-stage renal disease, severe renal impairment, or severe gastrointestinal disease.
Patients should be observed for signs of altered renal function, including those who are taking concomitant agents known to affect renal function/hydration status, such as diuretics, ACE inhibitors and NSAIDS, or those experiencing significant vomiting and/or diarrhea, which may lead to dehydration.
Patients receiving BYETTA with a sulfonylurea have an increased risk of hypoglycemia. To reduce the risk of hypoglycemia, clinicians may consider reducing the sulfonylurea dose.

Drug Interactions:

The effect of BYETTA to slow gastric emptying may reduce the extent and rate of absorption of orally administered drugs, so it should be used with caution in patients receiving oral medications that require rapid gastrointestinal absorption.
Medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, should be taken at least 1 hour before BYETTA injection. If such drugs are to be administered with food, they should be taken with a meal or snack when BYETTA is not administered.

Adverse Reactions:

The most common adverse events associated with BYETTA were nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, and dyspepsia.

For complete safety profile and other important prescribing considerations, see the accompanying full Prescribing Information.

The BYETTA mark and BYETTA design mark are trademarks of Amylin Pharmaceuticals, Inc.

BYETTA is available by prescription only.

ByettaHCP.com
amylin.com
LillyDiabetes.com
References

02-07-5549-A ©2007 Amylin Pharmaceuticals, Inc. and Eli Lilly and Company.
The BYETTA mark and BYETTA design mark are trademarks of Amylin Pharmaceuticals, Inc.

Indication:

Important Safety Information for BYETTA® (exenatide) injection

Precautions:

Drug Interactions:

Adverse Reactions:

Important Safety Information for BYETTA^® (exenatide) injection